Pharmacy procedures, page 4 of 5

Janus kinase inhibitor therapy

Use of a drug that inhibits Janus kinases. This page describes Janus kinase inhibitor therapy and where it is available across Weyland-Yutani Health System.

As a treatment, Janus kinase inhibitor therapy is planned with you. Talk with your care team about benefits, risks and alternatives.

Also known as

• JAK inhibitor therapy

Classification

Service type: therapeutic.

Ontology identifier: MAXO:0009096 (Medical Action Ontology).

Classification path: therapeutic procedure › pharmacotherapy.

Specialty: Pharmacy

Broader services

• pharmacotherapy

Used to treat

• obstructive sleep apnea
• chromosome 13q14 deletion syndrome
• lymphoproliferative syndrome 1
• COX deficiency, benign infantile mitochondrial myopathy
• borderline leprosy

Showing 5 of 9.

Preparing for your visit

Ask your clinician whether you need to fast, adjust medications or arrange a ride home before Janus kinase inhibitor therapy.

Available at

• Oregon City Orchard Health Center
• Longview Fairview Outpatient Center
• Longview Woodland Health Center

Providers offering this service

• Dr. Nia Ortiz, MD
• Dr. Sana Dang, MD
• Dr. Oscar Kim, MD
• Helen Li, NP
• Dr. Andre Ellis, MD

Showing 5 of 7.

Related articles

• Is Janus kinase inhibitor therapy Right for You?

Reference links

• http://purl.obolibrary.org/obo/MAXO_0009096

Macrolide antibacterial agent therapy

About this service. Use of a drug with a macrocyclic lactone with a ring of twelve or more members which exhibits antibiotic activity.

This is a therapeutic service. Your clinician will discuss goals, expected recovery and any follow-up care.

Also known as

• macrolide antibacterial drug therapy
• macrolide antibacterial therapy
• macrolide drug therapy
• macrolide drug treatment
• Treatment with a macrolide antibacterial agent
• Treatment with a macrolide antibacterial drug
• Treatment with a macrolide antibacterial medication
• Treatment with a macrolide antibiotic agent
• Treatment with a macrolide antibiotic drug
• Treatment with a macrolide antibiotic medication

Classification

Service type: therapeutic.

Ontology identifier: MAXO:0000200 (Medical Action Ontology).

Classification path: therapeutic procedure › pharmacotherapy › anti-infective agent therapy › antimicrobial agent therapy › antibacterial agent therapy.

Specialty: Pharmacy

Broader services

• antibacterial agent therapy

Used to treat

• angiosarcoma
• omphalocele
• glycogen storage disease IXb
• acquired von Willebrand syndrome
• cardiac tamponade

Showing 5 of 12.

Preparing for your visit

Your care team will give preparation instructions when you schedule. Call ahead if you have questions or need an interpreter.

Available at

• Portland Willow Creek Health Center
• Lake Oswego Woodland Health Center

Providers offering this service

• Dr. Nadia Taylor, MD
• Nathan Brooks, NP
• Dr. Carmen Cooper, MD
• Dr. Michael Banerjee, MD
• Dr. Jonah Chen, MD

Showing 5 of 9.

Reference links

• http://purl.obolibrary.org/obo/MAXO_0000200

Mast cell stabilizer agent therapy

Treatment with an agent that block mast cell degranulation, stabilizing the cell and thereby preventing the release of histamine and other factors thereby preventing or regulating allergic disorders. This page describes mast cell stabilizer agent therapy and where it is available across Weyland-Yutani Health System.

This is a therapeutic service. Your clinician will discuss goals, expected recovery and any follow-up care.

Also known as

• mast cell stabiliser agent therapy
• mast cell stabiliser drug treatment
• mast cell stabilizer drug treatment

Classification

Service type: therapeutic.

Ontology identifier: MAXO:0000320 (Medical Action Ontology).

Classification path: therapeutic procedure › pharmacotherapy › respiratory tract agent therapy.

Specialty: Pharmacy

Broader services

• respiratory tract agent therapy

Used to treat

• Polyomavirus-associated nephropathy
• amelogenesis imperfecta hypomaturation type 2A5
• short-rib thoracic dysplasia 11 with or without polydactyly
• severe congenital encephalopathy due to MECP2 mutation
• hypertensive heart disease

Showing 5 of 11.

Preparing for your visit

Your care team will give preparation instructions when you schedule. Call ahead if you have questions or need an interpreter.

Providers offering this service

• Dr. Nathan Gill, DO
• Dr. Aisha Gonzalez, MD
• Dr. Rafael Hall, MD
• Dr. Dominic Cooper, DO
• Dr. Tomas Burke, DO

Showing 5 of 8.

Related articles

• Is Mast cell stabilizer agent therapy Right for You?
• What to Expect: Mast cell stabilizer agent therapy

Reference links

• http://purl.obolibrary.org/obo/MAXO_0000320
• http://purl.obolibrary.org/obo/NCIT_C29714

Metabotropic glutamate receptor antagonist therapy

Use of a drug that selectively binds to and inhibits metabotropic glutamate receptors. Weyland-Yutani Health System offers metabotropic glutamate receptor antagonist therapy through Pharmacy.

This is a therapeutic service. Your clinician will discuss goals, expected recovery and any follow-up care.

Also known as

• treatment with metabotropic glutamate receptor antagonist
• treatment with metabotropic glutamate receptor blockade
• treatment with metabotropic glutamate receptor blocker
• treatment with mGluR antagonist

Classification

Service type: therapeutic.

Ontology identifier: MAXO:0000657 (Medical Action Ontology).

Classification path: therapeutic procedure › pharmacotherapy › molecular pathway modifying agent therapy › receptor antagonist therapy.

Specialty: Pharmacy

Broader services

• receptor antagonist therapy
• metabotropic glutamate receptor–targeting agent therapy

Used to treat

• Bardet-Biedl syndrome 16
• Charcot-Marie-Tooth disease recessive intermediate B
• marasmus
• male breast cancer
• Wernicke encephalopathy

Showing 5 of 8.

Preparing for your visit

Before your visit, confirm your appointment, bring your insurance card and tell staff about any allergies or medications.

Available at

• Portland Willow Creek Health Center
• Tualatin Willow Creek Clinic
• Longview Fairview Outpatient Center
• Forest Grove Riverside Specialty Clinic

Providers offering this service

• Dr. Emily Dang, DO
• Dr. Ethan Fischer, MD
• Dr. Karen Robinson, MD
• Dr. Ravi Dang, DO
• Dr. Helen Hill, DO

Showing 5 of 10.

Reference links

• http://purl.obolibrary.org/obo/MAXO_0000657

Metabotropic glutamate receptor–targeting agent therapy

Use of a drug that selectively binds to and regulates metabotropic glutamate receptors (mGluR). This page describes metabotropic glutamate receptor–targeting agent therapy and where it is available across Weyland-Yutani Health System.

As a treatment, metabotropic glutamate receptor–targeting agent therapy is planned with you. Talk with your care team about benefits, risks and alternatives.

Also known as

• treatment with metabotropic glutamate receptor modulator
• treatment with mGluR modulator

Classification

Service type: therapeutic.

Ontology identifier: MAXO:0000660 (Medical Action Ontology).

Classification path: therapeutic procedure › pharmacotherapy › central nervous system agent therapy › antidementia agent therapy › glutamatergic pathway modifying agent therapy.

Specialty: Pharmacy

Broader services

• glutamatergic pathway modifying agent therapy

More specific services

• metabotropic glutamate receptor antagonist therapy

Used to treat

• lissencephaly
• Weill-Marchesani syndrome
• acute myeloid leukemia without maturation
• Schwartz-Jampel syndrome 1
• external ear lipoma

Showing 5 of 12.

Preparing for your visit

Ask your clinician whether you need to fast, adjust medications or arrange a ride home before metabotropic glutamate receptor–targeting agent therapy.

Available at

• Oregon City Harbor Family Health Clinic

Providers offering this service

• Dr. Jin Young, MD
• Dr. Rosa Bailey, DO
• Dr. Joel Hussain, DO
• Dr. Claire Cohen, DO
• Dr. Emily Mehta, MD

Showing 5 of 13.

Reference links

• http://purl.obolibrary.org/obo/MAXO_0000660

MMP inhibitor agent therapy

Use of a drug or agent that inhibits matrix metalloprotease inhibitor. Weyland-Yutani Health System offers MMP inhibitor agent therapy through Pharmacy.

This is a therapeutic service. Your clinician will discuss goals, expected recovery and any follow-up care.

Also known as

• treatment with matrix metalloproteinase inhibitor

Classification

Service type: therapeutic.

Ontology identifier: MAXO:0001470 (Medical Action Ontology).

Classification path: therapeutic procedure › pharmacotherapy › molecular pathway modifying agent therapy › enzyme inhibitor agent therapy.

Specialty: Pharmacy

Broader services

• molecular pathway modifying agent therapy

Used to treat

• lymphocytic colitis
• familial cold autoinflammatory syndrome 4
• retinitis pigmentosa 57
• autosomal recessive nonsyndromic deafness 17
• intestinal infectious disease

Showing 5 of 11.

Preparing for your visit

Ask your clinician whether you need to fast, adjust medications or arrange a ride home before MMP inhibitor agent therapy.

Providers offering this service

• Dr. Hassan Zhou, MD
• Dr. Darius Fernandez, MD
• Samuel Kang, NP
• Dr. Darius Ramos, DO
• Dr. Adam Ho, DO

Showing 5 of 17.

Related articles

• MMP inhibitor agent therapy: Preparing and Recovering
• What to Expect: MMP inhibitor agent therapy

Reference links

• http://purl.obolibrary.org/obo/MAXO_0001470

Molecular pathway modifying agent therapy

molecular pathway modifying agent therapy: Treatment with an agent that modifies a particular molecular pathway.

This is a therapeutic service. Your clinician will discuss goals, expected recovery and any follow-up care.

Also known as

• CHEBI:52206
• treatment with biochemical role

Classification

Service type: therapeutic.

Ontology identifier: MAXO:0000644 (Medical Action Ontology).

Classification path: therapeutic procedure › pharmacotherapy.

Specialty: Pharmacy

Broader services

• pharmacotherapy

More specific services

• receptor antagonist therapy
• tetracycline therapy
• sodium channel inhibitor therapy
• glutamatergic pathway modifying agent therapy
• ACE2 inhibitor therapy
• phosphodiesterase inhibitor therapy
• MMP inhibitor agent therapy
• sodium-glucose cotransporter-2 inhibitor therapy

Used to treat

• microscopic colitis
• Noonan syndrome 6
• Alzheimer's disease 13
• strabismic amblyopia
• Graves' disease

Showing 5 of 11.

Preparing for your visit

Ask your clinician whether you need to fast, adjust medications or arrange a ride home before molecular pathway modifying agent therapy.

Available at

• Lake Oswego Maple Park Family Health Clinic

Providers offering this service

• Dr. Ravi Patel, MD
• Dr. Eli Lee, MD
• Dr. Rachel Doan, MD
• Dr. Nadia Taylor, MD
• Dr. Victor Ahmed, DO

Showing 5 of 18.

Reference links

• http://purl.obolibrary.org/obo/MAXO_0000644

Monoamine-depleting agent therapy

About this service. Treatment with a group of drugs which reversibly deplete one or more monoamine neurotransmitters.

As a treatment, monoamine-depleting agent therapy is planned with you. Talk with your care team about benefits, risks and alternatives.

Classification

Service type: therapeutic.

Ontology identifier: MAXO:0001544 (Medical Action Ontology).

Classification path: therapeutic procedure › pharmacotherapy.

Specialty: Pharmacy

Broader services

• pharmacotherapy

Used to treat

• erythrokeratodermia variabilis
• lymphocytic colitis
• hypogonadotropic hypogonadism 5 with or without anosmia
• Alzheimer's disease 10
• atrial heart septal defect 5

Showing 5 of 14.

Preparing for your visit

Your care team will give preparation instructions when you schedule. Call ahead if you have questions or need an interpreter.

Providers offering this service

• David Olsen, NP
• Dr. David Kaur, MD
• Dr. Uma Okafor, DO
• Dr. Elena Hughes, MD
• Dr. Benjamin Anderson, DO

Showing 5 of 8.

Reference links

• http://purl.obolibrary.org/obo/MAXO_0001544

Muscarinic agonist therapy

muscarinic agonist therapy: Treatment with drug or agent to activate muscarinic signaling.

As a treatment, muscarinic agonist therapy is planned with you. Talk with your care team about benefits, risks and alternatives.

Also known as

• treatment with muscarinic agonist

Classification

Service type: therapeutic.

Ontology identifier: MAXO:0001325 (Medical Action Ontology).

Classification path: therapeutic procedure › pharmacotherapy › neurotransmitter agent therapy › cholinergic agent therapy › cholinergic agonist therapy.

Specialty: Pharmacy

Broader services

• neurotransmitter agent therapy

Used to treat

• Charcot-Marie-Tooth disease type 4B2
• placental choriocarcinoma
• lymphangitis
• meningitis

Preparing for your visit

Your care team will give preparation instructions when you schedule. Call ahead if you have questions or need an interpreter.

Available at

• Lake Oswego Southgate Specialty Clinic
• Klamath Falls Valley Medical Center

Providers offering this service

• Jorge Doan, NP
• Dr. Valeria Yang, DO
• Dr. Andre Turner, DO
• Dr. Uma Hernandez, MD
• Dr. Jamal Wong, MD

Showing 5 of 11.

Related articles

• What to Expect: Muscarinic agonist therapy

Reference links

• http://purl.obolibrary.org/obo/MAXO_0001325

Muscarinic antagonist therapy

Treatment with a drug or agent to inhibit muscarinic signaling. This page describes muscarinic antagonist therapy and where it is available across Weyland-Yutani Health System.

As a treatment, muscarinic antagonist therapy is planned with you. Talk with your care team about benefits, risks and alternatives.

Also known as

• treatment with muscarinic antagonist

Classification

Service type: therapeutic.

Ontology identifier: MAXO:0001328 (Medical Action Ontology).

Classification path: therapeutic procedure › pharmacotherapy › neurotransmitter agent therapy › cholinergic agent therapy › cholinergic antagonist therapy.

Specialty: Pharmacy

Broader services

• cholinergic antagonist therapy

Used to treat

• exanthema subitum
• congenital muscular dystrophy
• autosomal recessive nonsyndromic deafness 98
• antisocial personality disorder
• cartilage disease

Showing 5 of 8.

Preparing for your visit

Your care team will give preparation instructions when you schedule. Call ahead if you have questions or need an interpreter.

Available at

• Roseburg Southgate Outpatient Center

Providers offering this service

• Dr. Yuki Quinn, MD
• Dr. Noah Bianchi, MD
• Samir Gupta, NP
• Dr. Javier Kelly, MD
• Dr. Zainab Li, MD

Showing 5 of 18.

Reference links

• http://purl.obolibrary.org/obo/MAXO_0001328

Nicotinic acid agent therapy

Treatment with an agent that works through, or mimics, the action of niacin. Our Pharmacy team performs nicotinic acid agent therapy and explains each step beforehand.

This is a therapeutic service. Your clinician will discuss goals, expected recovery and any follow-up care.

Classification

Service type: therapeutic.

Ontology identifier: MAXO:0000740 (Medical Action Ontology).

Classification path: therapeutic procedure › pharmacotherapy › cardiovascular agent therapy › dyslipidemic agent therapy.

Specialty: Pharmacy

Broader services

• cardiovascular agent therapy

Used to treat

• xeroderma pigmentosum
• hypoparathyroidism-retardation-dysmorphism syndrome
• congenital diarrhea 7 with exudative enteropathy
• Alzheimer's disease 13
• Charcot-Marie-Tooth disease type 4G

Showing 5 of 15.

Preparing for your visit

Before your visit, confirm your appointment, bring your insurance card and tell staff about any allergies or medications.

Providers offering this service

• Ali Hernandez, NP
• Dr. Kofi Hamilton, MD
• Dr. Khalid Abbott, MD
• Dr. Javier Castillo, DO
• Dr. Jorge Perez, MD

Showing 5 of 11.

Reference links

• http://purl.obolibrary.org/obo/MAXO_0000740
• http://purl.obolibrary.org/obo/NCIT_C98151

NMDA receptor modulator agent therapy

Use of a drug that modulates the action of N-methyl-D-aspartate (NMDA) receptors. Our Pharmacy team performs NMDA receptor modulator agent therapy and explains each step beforehand.

This is a therapeutic service. Your clinician will discuss goals, expected recovery and any follow-up care.

Also known as

• Treatment with NMDA receptor modulator

Classification

Service type: therapeutic.

Ontology identifier: MAXO:0000658 (Medical Action Ontology).

Classification path: therapeutic procedure › pharmacotherapy › central nervous system agent therapy › antidementia agent therapy › glutamatergic pathway modifying agent therapy.

Specialty: Pharmacy

Broader services

• glutamatergic pathway modifying agent therapy

Used to treat

• Loeys-Dietz syndrome
• generalized dystonia
• retinitis pigmentosa 19
• parotitis
• acquired night blindness

Showing 5 of 12.

Preparing for your visit

Before your visit, confirm your appointment, bring your insurance card and tell staff about any allergies or medications.

Providers offering this service

• Dr. Jonah Zhou, DO
• Dr. Kai Campbell, MD
• Dr. Jasmine Cooper, MD
• Dr. Adrian Brown, DO
• Dr. Gabriel Brooks, MD

Showing 5 of 19.

Related articles

• NMDA receptor modulator agent therapy: Preparing and Recovering
• Questions to Ask About NMDA receptor modulator agent therapy

Reference links

• http://purl.obolibrary.org/obo/MAXO_0000658

Non-nucleoside reverse transcriptase inhibitor therapy

Treatment with a substance structurally unlike a nucleoside molecule that is capable of inhibiting the function of a reverse transcriptase. These compounds do not bind to the active site of the polymerase but in a less conserved pocket near the active site, causing a distortion in the shape of the active site and resulting in inhibition of enzymatic function, chain termination, and inhibition of viral replication. Our Pharmacy team performs non-nucleoside reverse transcriptase inhibitor therapy and explains each step beforehand.

As a treatment, non-nucleoside reverse transcriptase inhibitor therapy is planned with you. Talk with your care team about benefits, risks and alternatives.

Also known as

• anti-HIV non-nucleoside reverse transcriptase inhibitor drug therapy
• anti-HIV non-nucleoside reverse transcriptase inhibitor drug treatment
• treatment with anti-HIV therapy, non-nucleoside reverse transcriptase inhibitor agent
• treatment with anti-HIV therapy, non-nucleoside reverse transcriptase inhibitor drug
• treatment with anti-HIV therapy, non-nucleoside reverse transcriptase inhibitor medication

Classification

Service type: therapeutic.

Ontology identifier: MAXO:0000250 (Medical Action Ontology).

Classification path: therapeutic procedure › pharmacotherapy › anti-infective agent therapy › antimicrobial agent therapy › antiviral agent therapy › anti-HIV agent therapy.

Specialty: Pharmacy

Broader services

• anti-HIV agent therapy

Used to treat

• congenital diarrhea 6
• sialadenitis
• pneumoconiosis
• meningocele
• protein-energy malnutrition

Showing 5 of 10.

Preparing for your visit

Your care team will give preparation instructions when you schedule. Call ahead if you have questions or need an interpreter.

Available at

• Albany Sunset Medical Center

Providers offering this service

• Dr. Omar Jones, MD
• Dr. Darius Aguilar, MD
• Dr. Chen Bailey, MD
• Dr. Caleb Brooks, MD
• Dr. Chen Cohen, DO

Showing 5 of 21.

Reference links

• http://purl.obolibrary.org/obo/MAXO_0000250
• http://purl.obolibrary.org/obo/NCIT_C97453

NSAID therapy

Treatment with an anti-inflammatory drug that is not a steroid. In addition to anti-inflammatory actions, non-steroidal anti-inflammatory drugs have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Weyland-Yutani Health System offers NSAID therapy through Pharmacy.

As a treatment, NSAID therapy is planned with you. Talk with your care team about benefits, risks and alternatives.

Also known as

• non-steroidal anti-inflammatory medication treatment
• treatment with non-steroidal anti-inflammatory drug
• treatment with non-steroidal anti-inflammatory medication
• treatment with NSAID drug
• treatment with NSAID medication
• treatment with NSAID therapy

Classification

Service type: therapeutic.

Ontology identifier: MAXO:0000221 (Medical Action Ontology).

Classification path: therapeutic procedure › pharmacotherapy › anti-inflammatory agent therapy › antirheumatic agent therapy.

Specialty: Pharmacy

Broader services

• pharmacotherapy

Used to treat

• Streptococcus pneumonia
• pontocerebellar hypoplasia
• lethal congenital contracture syndrome
• microphthalmia with limb anomalies
• autosomal dominant nonsyndromic deafness 53

Showing 5 of 12.

Preparing for your visit

Before your visit, confirm your appointment, bring your insurance card and tell staff about any allergies or medications.

Available at

• Gresham Sunset Medical Center
• Portland Hillcrest Medical Center

Providers offering this service

• Nora Abbott, NP
• Dr. Anika Martin, DO
• Dr. Tomas Morgan, MD
• Dr. Amir Bennett, MD
• Dr. Angela Gill, MD

Showing 5 of 11.

Related articles

• What to Expect: NSAID therapy

Reference links

• http://purl.obolibrary.org/obo/MAXO_0000221

Nucleoside and nucleotide reverse transcriptase inhibitor therapy

About this service. Treatment with nucleoside reverse transcriptase inhibitors (NRTIs) which block reverse transcriptase (an HIV enzyme).

As a treatment, nucleoside and nucleotide reverse transcriptase inhibitor therapy is planned with you. Talk with your care team about benefits, risks and alternatives.

Also known as

• anti-HIV nucleoside and nucleotide reverse transcriptase inhibitor drug treatment
• NRTI drug therapy
• treatment with NRTI agent
• treatment with NRTI drug
• treatment with NRTI medication
• treatment with nucleoside and nucleotide reverse transcriptase inhibitor medication
• treatment with nucleoside-nucleotide reverse transcriptase inhibitor drug
• treatment with nucleoside-nucleotide reverse transcriptase inhibitor medication
• treatment with nucleoside/nucleotide reverse transcriptase inhibitor drug
• treatment with nucleoside/nucleotide reverse transcriptase inhibitor medication

Classification

Service type: therapeutic.

Ontology identifier: MAXO:0000251 (Medical Action Ontology).

Classification path: therapeutic procedure › pharmacotherapy › anti-infective agent therapy › antimicrobial agent therapy › antiviral agent therapy › anti-HIV agent therapy.

Specialty: Pharmacy

Broader services

• anti-HIV agent therapy

Used to treat

• Hennekam syndrome
• bone disease
• cataract 4 multiple types
• retinitis pigmentosa 37
• autosomal dominant nonsyndromic deafness 10

Showing 5 of 19.

Preparing for your visit

Your care team will give preparation instructions when you schedule. Call ahead if you have questions or need an interpreter.

Available at

• Newberg Willow Creek Family Health Clinic
• Troutdale Meadowbrook Health Center

Providers offering this service

• Dr. Rosa Hassan, DO
• Dr. Kai Sharma, MD
• Nora Abbott, NP
• Dr. Joseph Bianchi, DO
• Dr. Miguel Perez, MD

Showing 5 of 11.

Related articles

• Questions to Ask About Nucleoside and nucleotide reverse transcriptase inhibitor therapy

Reference links

• http://purl.obolibrary.org/obo/MAXO_0000251

Opioid analgesic agent therapy

opioid analgesic agent therapy: Use of a narcotic or opioid substance, synthetic or semisynthetic agent producing profound analgesia, drowsiness, and changes in mood.

As a treatment, opioid analgesic agent therapy is planned with you. Talk with your care team about benefits, risks and alternatives.

Also known as

• narcotic analgesic medication therapy
• narcotic analgesic medication treatment
• narcotic analgesic therapy
• opioid analgesic drug therapy
• opioid analgesic medication therapy
• opioid analgesic medication treatment
• opioid analgesics
• opioid therapy
• treatment with opioid analgesic

Classification

Service type: therapeutic.

Ontology identifier: MAXO:0000194 (Medical Action Ontology).

Classification path: therapeutic procedure › pharmacotherapy › analgesic agent therapy.

Specialty: Pharmacy

Broader services

• pharmacotherapy
• pain management

Used to treat

• Polyomavirus-associated nephropathy
• autosomal dominant cutis laxa
• Alzheimer's disease 13
• Charcot-Marie-Tooth disease axonal type 2L
• autosomal recessive nonsyndromic deafness 98

Showing 5 of 20.

Preparing for your visit

Ask your clinician whether you need to fast, adjust medications or arrange a ride home before opioid analgesic agent therapy.

Providers offering this service

• Dr. Aria Ho, MD
• Dr. Jessica Obi, MD
• Dr. Amir Bennett, MD
• Claire Hernandez, NP
• Dr. Ravi Andersson, MD

Showing 5 of 7.

Reference links

• http://purl.obolibrary.org/obo/MAXO_0000194

Orphan drug therapy

A drug or pharmaceutical agent that is developed to treat a rare medical condition. This page describes orphan drug therapy and where it is available across Weyland-Yutani Health System.

As a treatment, orphan drug therapy is planned with you. Talk with your care team about benefits, risks and alternatives.

Also known as

• orphan drug treatment
• treatment with orphan drug

Classification

Service type: therapeutic.

Ontology identifier: MAXO:0001500 (Medical Action Ontology).

Classification path: therapeutic procedure › pharmacotherapy.

Specialty: Pharmacy

Broader services

• pharmacotherapy

Used to treat

• congenital disorder of glycosylation type IIh
• small fiber neuropathy
• hypogonadotropic hypogonadism
• autosomal dominant isolated macrothrombocytopenia 1
• factor VIII deficiency

Showing 5 of 11.

Preparing for your visit

Before your visit, confirm your appointment, bring your insurance card and tell staff about any allergies or medications.

Available at

• Canby Parkside Family Health Clinic

Providers offering this service

• Dr. Amara Fischer, MD
• Dr. Caleb Morales, DO
• Dr. Yasmin Chowdhury, DO
• Dr. Adrian Banerjee, MD
• Dr. Rachel Alvarez, DO

Showing 5 of 9.

Related articles

• What to Expect: Orphan drug therapy

Reference links

• http://purl.obolibrary.org/obo/MAXO_0001500

Pharmacotherapy

About this service. Use of a substance introduced into a living organism with therapeutic or diagnostic purpose.

As a treatment, pharmacotherapy is planned with you. Talk with your care team about benefits, risks and alternatives.

Also known as

• drug treatment
• medication therapy
• pharmaceutical drug
• pharmaceutical treatment
• pharmacological treatment

Classification

Service type: therapeutic.

Ontology identifier: MAXO:0000058 (Medical Action Ontology).

Classification path: therapeutic procedure.

Specialty: Pharmacy

More specific services

• mood and behavior-altering agent therapy
• antineoplastic therapy
• antiparasititic agent therapy
• antidementia agent therapy
• therapeutic antidotes, deterrents, and toxicologic agent therapy
• coagulant agent therapy
• blood formation agent therapy
• cardiovascular agent therapy
• non-opioid analgesic therapy
• opioid analgesic agent therapy
• calcium channel modifying agent therapy
• sodium channel inhibitor therapy
• serotonin-norepinephrine reuptake inhibitor agent therapy
• NSAID therapy
• antimyasthenic agent therapy
• atypical antipsychotic agent therapy
• antidepressant anxiolytics
• glycemic agent therapy
• dermatological agent therapy
• gastrointestinal agent therapy
• gastrointestinal antispasmodics agent therapy
• genitourinary agent therapy
• hormone modifying therapy
• immunological agent therapy
• ophthalmic agent therapy

Showing 25 of 53.

Used to treat

• exanthema subitum
• reticulate acropigmentation of Kitamura
• Leber congenital amaurosis 5
• cataract 8 multiple types
• cataract 6 multiple types

Showing 5 of 15.

Preparing for your visit

Your care team will give preparation instructions when you schedule. Call ahead if you have questions or need an interpreter.

Available at

• Canby Evergreen Health Center
• Oregon City Harbor Family Health Clinic
• Forest Grove Maple Park Family Health Clinic

Providers offering this service

• Dr. Paula Olsen, MD
• Dr. Nia Ortiz, MD
• Dr. Adrian Schmidt, MD
• Dr. Wei Nguyen, MD
• Dr. Alexis Reed, MD

Showing 5 of 15.

Related articles

• Pharmacotherapy: Preparing and Recovering

Reference links

• http://purl.obolibrary.org/obo/MAXO_0000058

Phosphodiesterase inhibitor therapy

Treatment with a phosphodiesterase (PDE) inhibitor. This page describes phosphodiesterase inhibitor therapy and where it is available across Weyland-Yutani Health System.

This is a therapeutic service. Your clinician will discuss goals, expected recovery and any follow-up care.

Also known as

• PDE inhibitor therapy

Classification

Service type: therapeutic.

Ontology identifier: MAXO:0000908 (Medical Action Ontology).

Classification path: therapeutic procedure › pharmacotherapy › molecular pathway modifying agent therapy › enzyme inhibitor agent therapy.

Specialty: Pharmacy

Broader services

• molecular pathway modifying agent therapy

More specific services

• phosphodiesterase inhibitor bronchodilator agent therapy

Used to treat

• hemophagocytic lymphohistiocytosis
• chromosome 15q26-qter deletion syndrome
• Leber congenital amaurosis 13
• spastic diplegia
• diabetic angiopathy

Showing 5 of 10.

Preparing for your visit

Ask your clinician whether you need to fast, adjust medications or arrange a ride home before phosphodiesterase inhibitor therapy.

Available at

• Lake Oswego Heritage Clinic
• Tigard Cedar Hills Clinic

Providers offering this service

• Dr. Sana Liu, DO
• Jin Obi, NP
• Dr. Darius Doan, MD
• Dr. Darius Banerjee, MD
• Dr. Javier Flores, MD

Showing 5 of 10.

Related articles

• Phosphodiesterase inhibitor therapy: Preparing and Recovering
• Phosphodiesterase inhibitor therapy: Preparing and Recovering
• Is Phosphodiesterase inhibitor therapy Right for You?

Reference links

• http://purl.obolibrary.org/obo/MAXO_0000908

Potassium-sparing diuretic agent therapy

Treatment with a diuretic agent that produces diuresis without increasing potassium excretion. Our Pharmacy team performs potassium-sparing diuretic agent therapy and explains each step beforehand.

This is a therapeutic service. Your clinician will discuss goals, expected recovery and any follow-up care.

Also known as

• treatment with potassium-sparing diuretic

Classification

Service type: therapeutic.

Ontology identifier: MAXO:0000741 (Medical Action Ontology).

Classification path: therapeutic procedure › pharmacotherapy › cardiovascular agent therapy › diuretic agent therapy.

Specialty: Pharmacy

Broader services

• diuretic agent therapy

Used to treat

• exanthema subitum
• acrorenal syndrome
• laryngomalacia
• progressive osseous heteroplasia
• hepatic encephalopathy

Showing 5 of 12.

Preparing for your visit

Before your visit, confirm your appointment, bring your insurance card and tell staff about any allergies or medications.

Available at

• Roseburg Southgate Outpatient Center
• Troutdale Meadowbrook Health Center

Providers offering this service

• Dr. Leila Chandra, MD
• Dr. Zoe Walker, DO
• Dr. Ibrahim Chen, MD
• Dr. Nathan Bell, MD
• Dr. Linh Obi, MD

Showing 5 of 11.

Reference links

• http://purl.obolibrary.org/obo/MAXO_0000741
• http://purl.obolibrary.org/obo/NCIT_C49186